Replies to post #75197 on PharmaCyte Biotech Inc (PMCB)

[Triple9]

I do believe we are very close and the excitement is monumental!

On Sept 6th $PMCB IR noted that KW was in Boston:

This picture was not taken in Boston. It was only uploaded while the CEO is in Boston to meet with Dr. Hidalgo, who is the Principal Investigator for the company's upcoming pivotal clinical trial in LAPC.

https://www.facebook.com/pharmacytebiotech/photos/pb.404679473033875.-2207520000.1505666302./838601716308313/?type=3&theater


Dr. Hidalgo, MD, PhD, is going to be our Principal Investigator and he is:

A Professor at Harvard Medical School

Member of Dana-Farber Harvard Cancer Center

Chief of Hematology Oncology at the Beth Israel Deaconess Medical Center

Director of Rosenberg Clinical Cancer Center at the Beth Israel Deaconess Medical Center

Co-Director of the Pancreatic Cancer Research Program at the Beth Israel Deaconess Medical Center

Here is one of Dr. Hidalgo's, MD, PhD, co-authored, peer-reviewed publications on "Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study" from January 2017.

https://www.ncbi.nlm.nih.gov/pubmed/27870574

TD2 is carefully crafting our IND with invaluable guidance from Dr. Hidaglo and Dr. Sher and all the other distinguished doctors in $PMCB's Management, Board and Advisory Boards.